State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, P.R. China.
Adv Exp Med Biol. 2021;1283:63-71. doi: 10.1007/978-981-15-8104-5_5.
H3G34 mutations occur in both pediatric non-brainstem high-grade gliomas (G34R/V) and giant cell tumors of bone (G34W/L). Glioblastoma patients with G34R/V mutation have a generally adverse prognosis, whereas giant cell tumors of bone are rarely metastatic benign tumors. G34 mutations possibly disrupt the epigenome by altering H3K36 modifications, which may involve attenuating the function of SETD2 at methyltransferase. H3K36 methylation change may further lead to genomic instability, dysregulated gene expression pattern, and more mutations. In this chapter, we summarize the pathological features of each mutation type in its respective cancer, as well as the potential mechanism of their disruption on the epigenome and genomic instability. Understanding each mutation type would provide a thorough background for a thorough understanding of the cancers and would bring new insights for future investigations and the development of new precise therapies.
H3G34 突变发生于儿童非脑干高级别胶质瘤(G34R/V)和骨巨细胞瘤(G34W/L)中。携带 G34R/V 突变的胶质母细胞瘤患者预后通常较差,而骨巨细胞瘤则是罕见的转移性良性肿瘤。G34 突变可能通过改变 H3K36 修饰来破坏表观基因组,这可能涉及削弱 SETD2 作为甲基转移酶的功能。H3K36 甲基化的改变可能进一步导致基因组不稳定性、基因表达模式失调和更多的突变。在本章中,我们总结了每种突变类型在其相应癌症中的病理特征,以及它们对表观基因组和基因组不稳定性的潜在破坏机制。了解每种突变类型将为深入了解癌症提供全面的背景,并为未来的研究和新的精确治疗方法的发展带来新的见解。